No Data
Two Sessions Time | National People's Congress Representative, Lu Qingguo from Chenguang Biotech Group: Improve the quality standards of Chinese Patent Medicine, regulate the centralized procurement model for Traditional Chinese Medicine, and optimize the
① Lu Qingguo, Director of Chenguang Biotech Group and a representative of the National People's Congress, focused on several recommendations at this year's Two Sessions, including optimizing the procurement mechanism for Traditional Chinese Medicine, enhancing the quality standards for Chinese Patent Medicine, and standardizing the Traditional Chinese Medicine granule industry; ② In addition to recommendations related to the Traditional Chinese Medicine industry, Lu Qingguo prepared several suggestions on rural social retirement insurance, rural medical insurance, and increasing support for companies sanctioned by the United States.
Is Lushang Freda Pharmaceutical Co.,Ltd.'s (SHSE:600223) Stock Price Struggling As A Result Of Its Mixed Financials?
Lushang Freda Pharmaceutical (600223.SH): Its two main brands, Aier Doctor and Yilian, have both settled in WeChat's small store.
According to Gelonghui on December 31, Lushang Freda Pharmaceutical (600223.SH) stated on the investor interaction platform that its two main brands, All Doctor and Yilian, have both entered WeChat's small store, fully connecting multiple traffic entrances such as public accounts, video accounts, search, and mini programs. Guangxi Tencent Venture Capital Co., Ltd. Holds 8.04% equity in the company’s subsidiary, ShanDong Lushang Freda Bio-Technology Co., Ltd.
Lushang Freda Pharmaceutical (600223.SH): Currently has no involvement in Retirement business.
Gelonghui reported on December 27 that Lushang Freda Pharmaceutical (600223.SH) stated on the investor interaction platform that the company currently has no involvement in Retirement business.
Even With A 26% Surge, Cautious Investors Are Not Rewarding Lushang Freda Pharmaceutical Co.,Ltd.'s (SHSE:600223) Performance Completely
Private Companies Among Lushang Freda Pharmaceutical Co.,Ltd.'s (SHSE:600223) Largest Stockholders and Were Hit After Last Week's 5.4% Price Drop
Despite the Downward Trend in Earnings at Lushang Freda PharmaceuticalLtd (SHSE:600223) the Stock Climbs 5.4%, Bringing Five-year Gains to 157%
